Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RT303
- Development stage
- Preclinical
- Lead developer
- Revio Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
RT303 is a pharmaceutical candidate under development by Revio Therapeutics, specifically designed as an oral syrup reformulation of an existing, proven drug. It is part of Revio's pipeline of reformulation programs (RT301-RT308) aimed at optimizing drug delivery and patient outcomes. RT303 is being developed for the treatment of autoimmune diseases. As of the current pipeline status, the program is in the preclinical stage, specifically progressing through CMC (Chemistry, Manufacturing, and Controls) development or bridging studies. The specific identity of the active pharmaceutical ingredient and its molecular target have not been disclosed by the developer.
Beyond the preview
Go deeper on RT303.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RT303.